{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ferreira E"],"funding":["CI-IPOP","Portuguese Foundation for Science and Technology (FCT)","European Social Fund","Portuguese Oncology Institute of Porto—Research Centre","Fundação para a Ciência e Tecnologia","Porto Comprehensive Cancer Center Raquel Seruca","Norte Portugal Regional Operational Programme (NORTE 2020)","PT national funds (FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior)","Portuguese League Against Cancer","European Regional Development Fund"],"pagination":["3462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10971045"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(6)"],"pubmed_abstract":["Muscle-invasive bladder cancer (MIBC) remains a pressing health concern due to conventional treatment failure and significant molecular heterogeneity, hampering the development of novel targeted therapeutics. In our quest for novel targetable markers, recent glycoproteomics and bioinformatics data have pinpointed (glucose transporter 1) GLUT1 as a potential biomarker due to its increased expression in tumours compared to healthy tissues. This study explores this hypothesis in more detail, with emphasis on GLUT1 glycosylation patterns and cancer specificity. Immunohistochemistry analysis across a diverse set of human bladder tumours representing all disease stages revealed increasing GLUT1 expression with lesion severity, extending to metastasis, while remaining undetectable in healthy urot"],"journal":["International journal of molecular sciences"],"pubmed_title":["Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer."],"pmcid":["PMC10971045"],"funding_grant_id":["UIDP/00776/2020–5","SFRH/BD/142479/2018","CI-IPOP-29-2017–2020","CEECIND/03186/2017","LPCC-NRN 2024","2020.09384.BD","UIDP/00776/2020-5","UIDP/00776/2020","CI-IPOP-58-2017–2021","57/2016/CP1491/CT0002","2020.08708.BD","2022.08311.CEECIND","SFRH/BD/146500/2019","DL 57/2016/CP1491/CT0002"],"pubmed_authors":["Ferreira E","Ferreira D","Freitas R","Azevedo R","Relvas-Santos M","Afonso LP","Silva AMN","Ferreira JA","Santos B","Soares J","Lima L","Peixoto A","Santos LL","Goncalves M"],"additional_accession":[]},"is_claimable":false,"name":"Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.","description":"Muscle-invasive bladder cancer (MIBC) remains a pressing health concern due to conventional treatment failure and significant molecular heterogeneity, hampering the development of novel targeted therapeutics. In our quest for novel targetable markers, recent glycoproteomics and bioinformatics data have pinpointed (glucose transporter 1) GLUT1 as a potential biomarker due to its increased expression in tumours compared to healthy tissues. This study explores this hypothesis in more detail, with emphasis on GLUT1 glycosylation patterns and cancer specificity. Immunohistochemistry analysis across a diverse set of human bladder tumours representing all disease stages revealed increasing GLUT1 expression with lesion severity, extending to metastasis, while remaining undetectable in healthy urot","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-09T03:19:01.567Z","creation":"2025-04-04T23:53:21.678Z"},"accession":"S-EPMC10971045","cross_references":{"pubmed":["38542435"],"doi":["10.3390/ijms25063462"]}}